# Natural Killer Cells and Bortezomib to Treat Cancer

> **NCT00720785** · PHASE1 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 35 (actual)

## Conditions studied

- Chronic Myeloid Leukemia (CML)
- Pancreatic Ca
- Colon/Rectal Ca
- Multiple Myeloma
- Carcinoma, Non-Small -Cell Lung

## Interventions

- **DRUG:** Bortezomib
- **BIOLOGICAL:** NK cells

## Key facts

- **NCT ID:** NCT00720785
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-01
- **Primary completion:** 2021-04-06
- **Final completion:** 2021-04-06
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00720785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00720785, "Natural Killer Cells and Bortezomib to Treat Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00720785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*